Effect of Systemic Inflammatory Response to SARS-CoV-2 on Lopinavir and Hydroxychloroquine Plasma Concentrations

Author:

Marzolini Catia1ORCID,Stader Felix1,Stoeckle Marcel1,Franzeck Fabian12,Egli Adrian34,Bassetti Stefano5,Hollinger Alexa6,Osthoff Michael5,Weisser Maja1,Gebhard Caroline E.6,Baettig Veronika1,Geenen Julia5,Khanna Nina1,Tschudin-Sutter Sarah1,Mueller Daniel7,Hirsch Hans H.18,Battegay Manuel1,Sendi Parham19

Affiliation:

1. Division of Infectious Diseases & Hospital Hygiene, University Hospital Basel and University of Basel, Basel, Switzerland

2. Research and Analysis Services, University Hospital Basel and University of Basel, Basel, Switzerland

3. Division of Clinical Bacteriology and Mycology, University Hospital Basel, Basel, Switzerland

4. Applied Microbiology Research, Department of Biomedicine, University of Basel, Basel, Switzerland

5. Division of Internal Medicine and Department of Clinical Research, University Hospital Basel and University of Basel, Basel, Switzerland

6. Intensive Care Unit, University Hospital Basel, Basel, Switzerland

7. Institute of Clinical Chemistry, University Hospital Zurich, Zurich, Switzerland

8. Transplantation & Clinical Virology, Department of Biomedicine, University of Basel, Basel, Switzerland

9. Institute for Infectious Diseases, University of Bern, Bern, Switzerland

Abstract

Coronavirus disease 2019 (COVID-19) leads to inflammatory cytokine release, which can downregulate the expression of metabolizing enzymes. This cascade affects drug concentrations in the plasma. We investigated the association between lopinavir (LPV) and hydroxychloroquine (HCQ) plasma concentrations and the levels of the acute-phase inflammation marker C-reactive protein (CRP). LPV plasma concentrations in 92 patients hospitalized at our institution were prospectively collected. Lopinavir-ritonavir was administered every 12 hours, 800/200 mg on day 1 and 400/100 mg on day 2 until day 5 or 7.

Funder

Adolf and Mary Mil Foundation

Swiss National Foundation

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Reference42 articles.

1. Treatments Administered to the First 9152 Reported Cases of COVID-19: A Systematic Review

2. WHO. 2020. “Solidarity” clinical trial for COVID-19 treatments. https://www.who.int/emergencies/diseases/novel-coronavirus-2019/global-research-on-novel-coronavirus-2019-ncov/solidarity-clinical-trial-for-covid-19-treatments.

3. Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China

4. Rational Use of Tocilizumab in the Treatment of Novel Coronavirus Pneumonia

5. Regulation of drug metabolism and disposition during inflammation and infection

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3